Skip to content

Quark Pharmaceuticals presents results with siRNA for treatment of DMA and wet AMD

Quark Pharmaceuticals, based in Freemont California, have announced preliminary results of a study using a chemically modified siRNA to down regulate a gene known as “RTP801”, identified through a gene discovery programme at the company’s research facility.